Last reviewed · How we verify
Epalrestat,Mecobalamin
Epalrestat is a prostacyclin analog that inhibits platelet aggregation and improves microcirculation, while mecobalamin is a cobalamin derivative that supports nerve function and myelin formation.
Epalrestat is a prostacyclin analog that inhibits platelet aggregation and improves microcirculation, while mecobalamin is a cobalamin derivative that supports nerve function and myelin formation. Used for Acute ischemic stroke, Peripheral neuropathy, Diabetic neuropathy.
At a glance
| Generic name | Epalrestat,Mecobalamin |
|---|---|
| Sponsor | Xiangya Hospital of Central South University |
| Drug class | Prostacyclin analog + Cobalamin derivative combination |
| Target | Prostacyclin receptor (IP receptor) + Methylcobalamin-dependent enzymes |
| Modality | Small molecule |
| Therapeutic area | Neurology / Peripheral Neuropathy |
| Phase | FDA-approved |
Mechanism of action
Epalrestat acts as a prostacyclic acid derivative that reduces platelet aggregation, increases blood flow, and protects against ischemic injury in peripheral nerves. Mecobalamin is an active form of vitamin B12 that facilitates methylation reactions and supports neuronal metabolism, myelin synthesis, and nerve regeneration. Together, they are used to improve microcirculation and promote nerve recovery in peripheral neuropathies.
Approved indications
- Acute ischemic stroke
- Peripheral neuropathy
- Diabetic neuropathy
Common side effects
- Headache
- Dizziness
- Gastrointestinal disturbance
- Injection site reaction
Key clinical trials
- Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study (NA)
- Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epalrestat,Mecobalamin CI brief — competitive landscape report
- Epalrestat,Mecobalamin updates RSS · CI watch RSS
- Xiangya Hospital of Central South University portfolio CI